The Intellectual Property & Science business of Thomson Reuters has announced a collaboration with Orion Bionetworks to further the understanding of multiple sclerosis (MS) and advance the development of new therapies by generating predictive models of patient stratification and drug targets.
Orion Bionetworks is an alliance of leading organizations in patient care, computational modeling, translational research, and patient advocacy dedicated to transforming the study of brain disorders and accelerating the discovery of new therapies and the search for cures. In this project focused on advancing the understanding of the underlying biology of MS, the members of the alliance will combine their expertise and assets including biomarkers, disease system biology, high performance computing information technology and big data analytics to integrate and interpret clinical, molecular, imaging and real-world patient data to develop new predictive models for the disease.
Thomson Reuters Life Sciences Professional Services researchers use MetaBase, the company's flagship, manually curated database of protein interactions, biological pathways, disease biomarkers and medicinal chemistry, along with its unique collection of MS specific pathway maps and biomarkers, to construct predictive models that identify molecular subtypes, biomarkers, associated mechanisms and novel drug targets.
Thomson Reuters will provide Orion Bionetworks with the results of the modelling through access to the new MetaBase MS pathways and networks via the Thomson Reuters MetaCore platform, an integrated software suite for functional data analysis. The models will also be made available to the Alliance through tranSMART, an open source data sharing and analytics platform.
Thomson Reuters Life Sciences Professional Services is a multi-disciplinary team of molecular biologists, bioinformaticians, medicinal chemists and data scientists.
